These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 16875718

  • 1. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer.
    Chung HH, Kim MK, Kim JW, Park NH, Song YS, Kang SB, Lee HP.
    Gynecol Oncol; 2006 Dec; 103(3):1031-7. PubMed ID: 16875718
    [Abstract] [Full Text] [Related]

  • 2. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer.
    Kim K, Kang SB, Chung HH, Kim JW, Park NH, Song YS.
    Gynecol Oncol; 2008 Dec; 111(3):509-15. PubMed ID: 18851872
    [Abstract] [Full Text] [Related]

  • 3. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z.
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, Sanchez-Cespedes M.
    J Clin Oncol; 2006 Sep 10; 24(26):4333-9. PubMed ID: 16896002
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.
    Am J Clin Oncol; 2010 Oct 10; 33(5):489-94. PubMed ID: 20351547
    [Abstract] [Full Text] [Related]

  • 9. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH, Hua D, Du X.
    Cancer Chemother Pharmacol; 2009 Oct 10; 64(5):1001-7. PubMed ID: 19247656
    [Abstract] [Full Text] [Related]

  • 10. The impact of GGH -401C>T polymorphism on cisplatin-based chemoradiotherapy response and survival in cervical cancer.
    Silva IH, Nogueira-Silva C, Figueiredo T, Lombo L, Faustino I, Catarino R, Nogueira A, Pereira D, Medeiros R.
    Gene; 2013 Jan 10; 512(2):247-50. PubMed ID: 23107767
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma.
    Choi CH, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS.
    Gynecol Oncol; 2007 Jan 10; 104(1):64-9. PubMed ID: 16904170
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study.
    Chen H, Liang C, Zhang L, Huang S, Wu X.
    Gynecol Oncol; 2008 Sep 10; 110(3):308-15. PubMed ID: 18606439
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.